SEZanne: A Phase 2 Randomized, Open label, Multicenter Study to Evaluate the Optimal Dose, Safety, and Efficacy of ABBV-706 in Combination with Atezolizumab versus Standard of Care as First-Line Treatment in Subjects with Previously Untreated Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Condition studied
Small Cell Lung Cancer
Investigational medicinal product(s)
Eligibility
Primary endpoint
Progression-Free Survival (PFS) based on investigator assessment per RECIST v1.1.
Endpoint detail
Overall Response (OR) as Measured by Overall Response Rate (ORR) based on investigator assessment per RECIST v1.1., Duration of Response (DoR) based on investigator assessment per RECIST v1.1., Disease Control (DC) based on investigator assessment per RECIST v1.1., OS
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View 2024-517490-24-00 on CTIS ↗ ← All trials in the EU